After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...

Retatrutide, an experimental drug by Eli Lilly, shows promising results in weight loss by targeting three hormones, ...

Eli Lilly and Company (NYSE:LLY) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 5:15 PM ETCompany ParticipantsDave Ricks - Chairman ...

Eli Lilly & Co. (NYSE: LLY) is a major global pharmaceutical company in the medical sector. The company made headlines with ...

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...

The study's primary endpoint of progression ... the board of directors of Eli Lilly and Company (NYSE: LLY) approved a new $15 billion share repurchase program. The company's prior $5 billion ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / ACCESSWIRE / January 15, 2025 / Lexaria B ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

Older studies estimated a lower risk of dementia. According to new research, the number of people living with the disease in ...

Two medical spas have been sued by Eli Lilly for selling unapproved products that claim to contain tirzepatide. Tirzepatide ...